# Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

> **NCT00994292** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 1276 (actual)

## Conditions studied

- Acute Coronary Syndrome

## Interventions

- **DRUG:** YM150
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00994292
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-02
- **Final completion:** 2011-03
- **Target enrollment:** 1276 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994292, "Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00994292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*